COMP <GO>
CMND vs MRK // GROSS PROFIT MARGIN
Clearmind Medicine Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: CMND 0
— MRK 3
■ METRIC PARITY
LAST: $5.85 (-3.46%) • MKT CAP: $3.0M
gross-margins
—
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CMND VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CMND | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 20.70% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.42% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 34.30% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 28.10% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 1.30% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 7/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.2 | 51.7 | -8.49 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.0M | $361.02B | -$361.02B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CMND REV | MRK REV | CMND GROSS % | MRK GROSS % | CMND FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $65.01B | — | 74.8% | — | $12.36B |
| FY 2024 | — | $64.17B | — | 76.3% | — | $18.10B |
| FY 2023 | — | $60.12B | — | — | — | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CMND // BETA —
MRK // BETA 0.92